Gilder Gagnon Howe & Co’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-160,515	Closed	-$255K	–	341
2023 Q1	$255K	Sell	160,515 -992	-0.6%	-$1.8K	﹤0.01%	236
2022 Q4	$236K	Sell	161,507 -100	-0.1%	-$292	﹤0.01%	234
2022 Q3	$690K	Sell	161,607 -940	-0.6%	-$3.98K	0.01%	212
2022 Q2	$631K	Sell	162,547 -19,849	-11%	-$56.5K	0.01%	216
2022 Q1	$868K	Sell	182,396 -32,170	-15%	-$96.9K	0.01%	256
2021 Q4	$783K	Buy	214,566 +63,216	+42%	+$337K	﹤0.01%	305
2021 Q3	$1.21M	Buy	151,350 +476	+0.3%	+$4.69K	0.01%	318
2021 Q2	$1.71M	Buy	+150,874	New	+$1.51M	0.01%	309

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Gilder Gagnon Howe & Co's VIRX Position: Q2 2023 in Review

Gilder Gagnon Howe & Co sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2023, closing a stake of 160,515 shares — an estimated $255K sold.

Gilder Gagnon Howe & Co first reported a position in VIRX in Q2 2021 and held it in 8 quarters. The position peaked at $1.71M in Q2 2021. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2023.

Gilder Gagnon Howe & Co reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 160,515 Viracta Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $255K.
Gilder Gagnon Howe & Co first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Gilder Gagnon Howe & Co's Viracta Therapeutics, Inc. Common Stock position peaked at $1.71M in Q2 2021.
41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2023, filed 14 Aug 2023.